Archive for 30 diciembre 2010

Quirón vuelve

diciembre 30, 2010

Vuelve la mítica Quirón, la revista pionera de la bioética latinoamericana, ahora en formato digital, en su Volumen 40, Número 2.

Director Fundador José Alberto Mainetti

Director Asociado José Luis Mainetti

Editor Asociado Andrea Cajaraville

Coordinador Editorial José Pedro Ramos

Secretaría Administrativa Liliana Barletta

El número puede bajarse de http://phplist.e-microjuris.com.ar/imagenes/QuironVol40N2.pdf

Anuncios

Premio de bioética

diciembre 30, 2010

La Fundación Dr. Jaime Roca ha instituido el “Premio Anual de Bioética 2011 – Bioética de la Investigación en Salud”.

Esta distinción permite premiar a todo trabajo científico inédito realizado por egresados argentinos universitarios (médicos: profesiones auxiliares de la medicina; psicólogos; de carreras humanísticas o del derecho; de ciencias naturales y biológicas) y realizados en el país.

El mismo se otorgará a los tres mejores trabajos presentados sobre “Bioética de la Investigación en Salud”.

El Jurado está conformado por el Dr. José Alberto Mainetti, el Dr. Juan Carlos Tealdi y la Dra. María Luisa Preiffer.

Para ver el reglamento del concurso, click aquí.

Un debate para no perder

diciembre 24, 2010

En su excelente blog

Hooked: Ethics, Medicine, and Pharma

Howard Brody comenta el interesantísimo trabajo de Alastair Matheson “Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry” (BioSocieties 3:355-382, 2008).

El post de Brody se llama:

“How Commerce Reshapes Knowledge: Matheson on Pharma’s Influence on Science”.

Pero, no contento con eso, Brody le manda su comentario a Matheson, invitándolo a responder, lo que Matheson hace en un nuevo post

How Pharma Shapes Knowledge: Alastair Matheson Responds

Todo el intercambio es realmente muy interesante, y el trabajo de Matheson es esclarecedor.

Equipoise polémica

diciembre 24, 2010

Salim S. Abdool Karim, de la University of KwaZulu-Natal, Durban, South Africa, investigador principal del trabajo objetado por Philpott y Schüklenk, plantea la falta de standard previo y por lo tanto cuestiona la ausencia de verdadera equipoise:
“… the 2003 World Health Organization (WHO) guidelines, which were the basis of the 2004 South African guidelines, categorically state that recommendations on the initiation of antiretroviral therapy in tuberculosis are “provisional” and “pending ongoing studies,” since the “optimal time to initiate [antiretroviral agents] in patients with [tuberculosis] is not known.”1 Such tentative guidance can hardly be considered a definitive standard or a proven intervention. Further, a 2005 WHO consultation2 concluded that the “optimal time for initiating antiretroviral therapy” in coinfected patients is “the major research priority.” Thus, there was no conclusive evidence to define optimal HIV−tuberculosis therapy, and equipoise was never compromised.”

Ver en http://www.nejm.org/doi/full/10.1056/NEJMoa0905848#t=letters

De todos modos, Philpott y Schüklenk hacían también otros cuestionamientos (ver post anterior).

Bioethics Forum – A Study That Should Not Have Been Done

diciembre 24, 2010

Lúcido y recomendable análisis de Philpott y Schüklenk:

Bioethics Forum – A Study That Should Not Have Been Done.

Sean Philpott and Udo Schüklenk, 05/05/2010

A Study That Should Not Have Been Done

The New England Journal of Medicine in February published the results of a deeply flawed clinical trial in South Africa. The SAPIT (Starting Antiretroviral Therapy at Three Points in Tuberculosis Therapy) trial was designed to determine the most effective way to treat patients infected with HIV and tuberculosis. But it raises a number of disturbing questions about the oft-debated and vexing issue of appropriate standards of care in clinical trials undertaken in developing countries like South Africa. It also raises serious concerns about the quality of ethical review undertaken in those countries, and it highlights some surprising deficiencies in existing U.S. regulations regarding when ethical review should be undertaken by American IRBs.

Nuevo número de Health and Human Rights

diciembre 17, 2010

Table of Contents, Vol 12, No 2 (2010), Health and Human Rights

Social determinants of health: Convergences and disjunctures

Table of Contents and Frontmatter 

HHR 12.2 Journal

file Abstract file PDF

Collaborative imperatives, elusive dialogues [Editorial] 

Alicia Ely Yamin, Alec Irwin

file Abstract file HTML file PDF

Critical Concepts

The right to sutures: Social epidemiology, human rights, and social justice 

Sridhar Venkatapuram, Ruth Bell, Michael Marmot

file Abstract file HTML file PDF

The social determinants of health, health equity, and human rights 

Audrey R. Chapman

file Abstract file HTML file PDF

Social conditions, health equity, and human rights 

Paula Braveman

file Abstract file HTML file PDF

Health and Human Rights in Practice

Realizing human rights-based approaches for action on the social determinants of health 

Kumanan Rasanathan, Johanna Norenhag, Nicole Valentine

file Abstract file HTML file PDF

Human rights assessment in Parc Jean Marie Vincent, Port-au-Prince, Haiti 

Kimberly A. Cullen, Louise C. Ivers

file Abstract file HTML file PDF

Correlates of violence in Guinea’s Maison Centrale Prison: A statistical approach in documenting human rights abuses 

Ronald E. Osborn

file Abstract file HTML file PDF

Developing human rights-based strategies to improve health among female sex workers in Rwanda 

Agnès Binagwaho, Mawuena Agbonyitor, Aimable Mwananawe, Placidie Mugwaneza, Alec Irwin, Corine Karema

file Abstract file HTML file PDF

Nurses’ impoliteness as an impediment to patients’ rights in selected Kenyan hospitals 

Benson Oduor Ojwang, Emily Atieno Ogutu, Peter Maina Matu

file Abstract file HTML file PDF

Human rights consequences of mandatory HIV screening policy of newcomers to Canada 

Laura M. Bisaillon

file Abstract file HTML file PDF

Sex trafficking and health care in Metro Manila: Identifying social determinants to inform an effective health system response

Timothy P. Williams, Elaine J. Alpert, Roy Ahn, Elizabeth Cafferty, Wendy Macias Konstantopoulos, Nadya Wolferstan, Judith Palmer Castor, Anita M. McGahan, Thomas F. Burke

file Abstract file HTML file PDF

Pharmaceutical Industry Is Biggest Defrauder of the Federal Government Under the False Claims Act, New Public Citizen Study Finds | CommonDreams.org

diciembre 17, 2010

Pharmaceutical Industry Is Biggest Defrauder of the Federal Government Under the False Claims Act, New Public Citizen Study Finds | CommonDreams.org.

“Four companies (GlaxoSmithKline, Pfizer, Eli Lilly, and Schering-Plough) accounted for more than half (53 percent or $10.5 billion) of all financial penalties imposed over the past two decades. These leading violators were among the world’s largest pharmaceutical companies.”

50 Excellent Ethics Blogs Every Science Student Should Read

diciembre 15, 2010

Este blog ha sido incluido en esta lista, lo que agradecemos. Bioética Latinoamericana es el único blog de bioética en español incluido en la lista.

http://www.mastersdegree.net/blog/2010/50-excellent-ethics-blogs-every-science-student-should-read/